Study of Duvakitug for moderate to severe Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study tests a new drug called duvakitug to see if it can help maintain improvement in people with moderate to severe Crohn's disease. It's for patients who have already responded to treatment in a previous study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old (or 16-17 if you have reached Tanner stage 5 of development, where allowed by local rules)
- You have moderate to severe Crohn's disease and responded well to treatment in a previous study called STARSCAPE-1, with a follow-up endoscopy
- You are not allergic to duvakitug or have any other medical condition that would make the study unsafe for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
This trial tests a new medicine called brivekimig for people with moderate-to-severe Crohn's disease. It aims to see if the drug can reduce symptoms and inflammation better than standard treatments.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.